Melissa Lah
Clinical Molecular Genetics · Indianapolis, INNPI 1962607820
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 53.7% of the total. 2025 is the largest year on record at $54,438, 4.3 times the $12,629 reported in 2019.
Across 161 payments — averaging $855.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$74K
- PTC Therapeutics, Inc.$56K
- Travere Therapeutics, Inc.$3K
- Amgen$2K
- Soleno Therapeutics, Inc.$2K
- Modernatx, Inc.$1K
- plus $42 from 1 others
Across 229 payments — averaging $9906.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$832K
- Travere Therapeutics, Inc.$572K
- PTC Therapeutics, Inc.$549K
- Soleno Therapeutics, Inc.$155K
- Acadia Pharmaceuticals Inc$59K
- Recordati_rare_diseases_inc.$55K
- plus $46K from 5 others
What the payments were for
- Consulting fees$51,15937%
- Speaking & faculty fees$46,81634%
- Travel & lodging$31,41423%
- Food & beverage$4,6233%
- Education$3,7063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 95 | $73,904 |
| PTC Therapeutics, Inc. | 48 | $55,596 |
| Travere Therapeutics, Inc. | 4 | $3,087 |
| Amgen | 1 | $2,100 |
| Soleno Therapeutics, Inc. | 2 | $1,748 |
| Modernatx, Inc. | 10 | $1,242 |
| Sarepta Therapeutics, Inc. | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Palynziq$56,695
- Kuvan$3,951
- RAVICTI$2,100
- Diazoxide Choline Controlled Release (DCCR)$1,748
How this compares
Too few clinical molecular genetics providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PalynziqPegvaliase-Pqpz | 11 | $745,160 |
| JavygtorSapropterin Dihydrochloride | 22 | $223,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Palynziq | $73,904 | $745,16011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical molecular genetics providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other clinical molecular genetics in Indianapolis
- Bryan HainlineIndianapolis$28K
- Clair FrancomanoIndianapolis$2K
- Erin ConboyIndianapolis$155
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.